跳至主要内容
临床试验/ACTRN12613000512729
ACTRN12613000512729招募中1 期

A pilot study to evaluate safety and feasibility of administrating prophylactic doses of zoledronic acid to prevent symptomatic osteonecrosis following chemotherapy for acute lymphoblastic leukemia and lymphoma in children and adolescents.

Sydney Children's Hospital Network0 个研究点目标入组 10 人开始时间: 2013年5月8日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Prevention

入排标准

年龄范围
5 Years 至 16 Years(—)
性别
All

入选标准

  • 1)Diagnosis of Acute lymphoblastic leukemia or lymphoblastic lymphoma
  • 2)Age more than 10 years for Zoledronic acid intervention(group1)
  • 3)Age between 5yr-10 yr and able to have MRI without general anaesthetic for investigations (group2)

排除标准

  • 1)25 hydroxy vitamin D< 50 nmol/L
  • 2)Hypocalcemia corrected for albumin
  • 3)Prior bisphosphonate use
  • 4)Estimated glomerular filtration rate (GFR) <35ml/min/1.73 m2 at screening based on Schwartz formula
  • 5)Diagnosis of active uveitis
  • 6)History of primary bone disease (osteogenesis imperfecta, idiopathic juvenile osteoporosis, rickets/osteomalacia)
  • 7)Unable to have MRI without general anaesthesia

研究者

发起方
Sydney Children's Hospital Network

相似试验